AR003919A1 - Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dicha - Google Patents

Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dicha

Info

Publication number
AR003919A1
AR003919A1 ARP960101095A AR10109596A AR003919A1 AR 003919 A1 AR003919 A1 AR 003919A1 AR P960101095 A ARP960101095 A AR P960101095A AR 10109596 A AR10109596 A AR 10109596A AR 003919 A1 AR003919 A1 AR 003919A1
Authority
AR
Argentina
Prior art keywords
protein
accessory protein
human
interleukin
antibody
Prior art date
Application number
ARP960101095A
Other languages
English (en)
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR003919A1 publication Critical patent/AR003919A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP960101095A 1995-01-23 1996-01-19 Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dicha AR003919A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37626895A 1995-01-23 1995-01-23

Publications (1)

Publication Number Publication Date
AR003919A1 true AR003919A1 (es) 1998-09-30

Family

ID=23484321

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101095A AR003919A1 (es) 1995-01-23 1996-01-19 Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dicha

Country Status (19)

Country Link
EP (1) EP0808365A1 (fr)
JP (1) JPH10512453A (fr)
AR (1) AR003919A1 (fr)
AU (1) AU4537096A (fr)
BR (1) BR9606837A (fr)
CA (1) CA2210724A1 (fr)
CO (1) CO4480033A1 (fr)
CZ (1) CZ208197A3 (fr)
EA (1) EA199700265A1 (fr)
FI (1) FI973089A0 (fr)
HU (1) HUP9702458A2 (fr)
IL (1) IL116796A0 (fr)
MX (1) MX9705501A (fr)
NO (1) NO973404L (fr)
PE (1) PE64396A1 (fr)
PL (1) PL321538A1 (fr)
TR (1) TR199700652T1 (fr)
WO (1) WO1996023067A1 (fr)
ZA (1) ZA96333B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
AU7011696A (en) * 1996-08-26 1998-03-19 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
JP4771563B2 (ja) 1996-12-06 2011-09-14 アムジエン・インコーポレーテツド Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
CA2287876A1 (fr) * 1997-04-30 1998-11-05 F. Hoffmann-La Roche Ag Chemokine st38.2 du rat
US6280955B1 (en) * 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
JP2001526892A (ja) 1997-12-23 2001-12-25 イミュネックス・コーポレーション Ｓｉｇｉｒｒｄｎａおよびポリペプチド
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7049095B2 (en) 2000-10-31 2006-05-23 Immunex Corporation DNA encoding IL-1 receptor accessory protein
GB2375604A (en) * 2001-05-18 2002-11-20 Warner Lambert Co Methods for screening using interleukin soluble trimolecular complex
MXPA04000134A (es) 2001-06-26 2005-06-06 Abgenix Inc Anticuerpos para ligandos de osteoprotegerina.
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US20030049255A1 (en) * 2001-08-07 2003-03-13 Sims John E. Interleukin-1 receptors in the treatment of diseases
BRPI0314038B8 (pt) 2002-09-06 2021-05-25 Amgen Inc anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
AU2005231822B2 (en) 2004-04-02 2011-07-21 Swedish Orphan Biovitrum Ab (Publ) Methods of reducing aggregation of IL-1ra
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
CA2607113C (fr) * 2004-05-05 2013-11-12 Valorisation-Recherche, Societe En Commandite Antagonistes du recepteur de l'interleukine-1, compositions, et methodes de traitement
JP2008542685A (ja) * 2005-05-05 2008-11-27 ヴァロリザーシヨン・アッシュエスジ，ソシエテ・アン・コマンディット サイトカイン受容体修飾因子及びその使用
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
EP2271673B1 (fr) * 2008-03-26 2016-02-24 Cellerant Therapeutics, Inc. Récepteurs de cytokine associés aux troubles prolifératifs hématologiques myélogènes et utilisations correspondantes
EP2196476A1 (fr) 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
GB2472856B (en) * 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
DK2665749T3 (en) * 2011-01-19 2016-03-21 Cantargia Ab Anti-il1rap antibodies and their use for the treatment of solid tumors
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ， インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
CN103608030A (zh) * 2011-06-21 2014-02-26 昂科发克特公司 用于治疗和诊断癌症的组合物和方法
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
EP3294906B1 (fr) 2015-05-11 2024-07-10 Natera, Inc. Procédés pour la détermination de la ploïdie
EP3313887A2 (fr) 2015-06-26 2018-05-02 MAB Discovery GmbH Anticorps monoclonaux anti-il-1racp
EP3241845A1 (fr) 2016-05-06 2017-11-08 MAB Discovery GmbH Anticorps anti-il-1r3 humanisés
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
EP3401332A1 (fr) 2017-05-08 2018-11-14 MAB Discovery GmbH Anticorps anti-il-1r3 destinés à être utilisés dans des conditions inflammatoires
JP2020524519A (ja) 2017-06-20 2020-08-20 ザ メディカル カレッジ オブ ウィスコンシン，インコーポレイテッドＴｈｅ Ｍｅｄｉｃａｌ Ｃｏｌｌｅｇｅ ｏｆ Ｗｉｓｃｏｎｓｉｎ， Ｉｎｃ． 全セルフリーｄｎａによる移植合併症リスクの評価
JP2021506342A (ja) 2017-12-14 2021-02-22 ティーエーアイ ダイアグノスティックス インコーポレイテッドＴａｉ Ｄｉａｇｎｏｓｔｉｃｓ，Ｉｎｃ． 移植のための移植片適合性の評価
CA3090426A1 (fr) 2018-04-14 2019-10-17 Natera, Inc. Procedes de detection et de surveillance du cancer au moyen d'une detection personnalisee d'adn tumoral circulant
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2021236962A1 (fr) 2020-05-20 2021-11-25 The Medical College Of Wisconsin, Inc. Compositions et méthodes d'inhibition du syndrôme de libération des cytokines
WO2022247937A1 (fr) * 2021-05-28 2022-12-01 Biocytogen Jiangsu Co., Ltd. Animal non humain génétiquement modifié exprimant l'il1rap humaine ou chimérique
US12054552B2 (en) 2022-09-21 2024-08-06 Sanofi Biotechnology Humanized anti-IL-1R3 antibody and methods of use

Also Published As

Publication number Publication date
CZ208197A3 (en) 1997-11-12
BR9606837A (pt) 1998-05-26
IL116796A0 (en) 1996-05-14
FI973089A (fi) 1997-07-22
MX9705501A (es) 1997-10-31
PE64396A1 (es) 1997-01-28
JPH10512453A (ja) 1998-12-02
CO4480033A1 (es) 1997-07-09
WO1996023067A1 (fr) 1996-08-01
EP0808365A1 (fr) 1997-11-26
HUP9702458A2 (hu) 1998-04-28
TR199700652T1 (xx) 1998-02-21
AU4537096A (en) 1996-08-14
NO973404D0 (no) 1997-07-23
ZA96333B (en) 1996-07-23
CA2210724A1 (fr) 1996-08-01
PL321538A1 (en) 1997-12-08
EA199700265A1 (ru) 1998-04-30
NO973404L (no) 1997-07-23
FI973089A0 (fi) 1997-07-22

Similar Documents

Publication Publication Date Title
AR003919A1 (es) Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dicha
Vitaliano et al. The relative importance of risk factors in nonmelanoma carcinoma
Rosenthal et al. Seasonal affective disorders
Boucher The problems of vitamin d insufficiency in older people
Hammami et al. Differential effects of vitamin D2 and D3 supplements on 25-hydroxyvitamin D level are dose, sex, and time dependent: a randomized controlled trial
BR0213846A (pt) métodos de induzir seletivamente a apoptose nas células alvo que expressam dr5, de inibir a proliferação de células alvo que expressam dr5 e de tratar um paciente tendo uma doença inflamatória ou doença autoimune, e, composição
AR100225A2 (es) Anticuerpos anti-factor d humanizados y usos de los mismos
SV2003001148A (es) Derivados de benzamida tiazol y composciones farmaceuticas para inhibir la proliferacion de celulas, y metodos para su utilizacion ref. no.0097-01-sv
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
Fagan Remembering the lessons of basic pharmacology
DK1401422T3 (da) Halogenholdig sammensætning, fremgangsmåde til fremstilling heraf og anvendelser heraf
Abelaira et al. Ketamine exhibits different neuroanatomical profile after mammalian target of rapamycin inhibition in the prefrontal cortex: the role of inflammation and oxidative stress
Kim et al. Different patterns of emotional eating and visuospatial deficits whereas shared risk factors related with social support between anorexia nervosa and bulimia nervosa
Muders et al. Effects of Traumeel (Tr14) on Exercise‐Induced Muscle Damage Response in Healthy Subjects: A Double‐Blind RCT
ES2166770T3 (es) Anticuerpos monoclonales contra gangliosidos y sus utilizaciones en la inmunoterapia activa especifica de tumores malignos.
Akmese et al. Differential role of GABAergic and cholinergic ventral pallidal neurons in behavioral despair, conditioned fear memory and active coping
O’Connor et al. Endurance exercise attenuates juvenile irradiation-induced skeletal muscle functional decline and mitochondrial stress
ES2144054T3 (es) Complejos de tri(platino).
ES2061521T3 (es) Proteinas con actividad glutation-s-transferasa, secuencias de adn, anticuerpos, poxvirus y medicamentos para la prevencion de la equistosomiasis.
Dogra et al. Phototherapy and photochemotherapy in childhood dermatoses
Orjuela‐Grimm et al. Sunlight exposure in infancy decreases risk of sporadic retinoblastoma, extent of intraocular disease
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
Goldstein et al. Combined use of benserazide and carbidopa in Parkinson's disease
Baliño et al. Role of CA2+/calmodulin on ethanol neurobehavioral effects